Exploring dyslipidaemia, atherosclerotic diseases, and cardiovascular mortality, possibly positively influenced by favourable PON1 SNVs and optimal serum PON1 activity, we aimed to comment on PON1 and PON1 usefulness as future therapeutic targets in the management of HD patients. The gene discussed is PON1; the disease is inherited lipid metabolism disorder.